PMID- 28240404
OWN - NLM
STAT- MEDLINE
DCOM- 20171030
LR  - 20171030
IS  - 1610-0387 (Electronic)
IS  - 1610-0379 (Linking)
VI  - 15
IP  - 3
DP  - 2017 Mar
TI  - Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment 
      series in Austria.
PG  - 309-317
LID - 10.1111/ddg.13191 [doi]
AB  - BACKGROUND AND OBJECTIVES: Widely used in the treatment of psoriasis, biologics 
      have been tested in numerous clinical trials. However, drug efficacies and 
      adverse events (AEs) may differ in 'real-world' patients as they do not undergo 
      as rigorous selection and monitoring. Our objective was to examine drug survival, 
      efficacy, and AEs (quality, time of onset) in 'real-world' psoriasis patients 
      treated with etanercept, adalimumab, and ustekinumab. PATIENTS AND METHODS: 
      Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at 
      a psoriasis clinic in an Austrian hospital. All patients who had received at 
      least one dose of etanercept, adalimumab, or ustekinumab were included in the 
      analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity 
      Index (PASI), as well as quality and time of onset of AEs. RESULTS: In 209 
      treatment series, the estimated median drug survival varied among the various 
      treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for 
      adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment 
      with a biologic were positive predictors of longer drug survival in adalimumab. 
      We found no significant difference in drug efficacy as determined by PASI. 
      CONCLUSIONS: Most AEs occur during the first year of treatment. Adalimumab and 
      ustekinumab are marked by longer drug survival compared to etanercept.
CI  - (c) 2017 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & 
      Sons Ltd.
FAU - Richter, Leo
AU  - Richter L
AD  - Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
FAU - Vujic, Igor
AU  - Vujic I
AD  - Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
AD  - School of Medicine, Sigmund Freud University Vienna, Austria.
FAU - Sesti, Alma
AU  - Sesti A
AD  - Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
FAU - Monshi, Babak
AU  - Monshi B
AD  - Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
FAU - Sanlorenzo, Martina
AU  - Sanlorenzo M
AD  - Department of Medical Sciences, Section of Dermatology, University of Turin, 
      Italy.
FAU - Posch, Christian
AU  - Posch C
AD  - Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
AD  - School of Medicine, Sigmund Freud University Vienna, Austria.
FAU - Rappersberger, Klemens
AU  - Rappersberger K
AD  - Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20170227
PL  - Germany
TA  - J Dtsch Dermatol Ges
JT  - Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German 
      Society of Dermatology : JDDG
JID - 101164708
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - FU77B4U5Z0 (Ustekinumab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab/*administration & dosage
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Anti-Inflammatory Agents/administration & dosage
MH  - Austria/epidemiology
MH  - Child
MH  - Dermatologic Agents/administration & dosage
MH  - Etanercept/*administration & dosage
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Psoriasis/*drug therapy/*epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sex Distribution
MH  - Treatment Outcome
MH  - Ustekinumab/*administration & dosage
MH  - Young Adult
EDAT- 2017/02/28 06:00
MHDA- 2017/10/31 06:00
CRDT- 2017/02/28 06:00
PHST- 2016/06/14 00:00 [received]
PHST- 2016/07/08 00:00 [accepted]
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/10/31 06:00 [medline]
PHST- 2017/02/28 06:00 [entrez]
AID - 10.1111/ddg.13191 [doi]
PST - ppublish
SO  - J Dtsch Dermatol Ges. 2017 Mar;15(3):309-317. doi: 10.1111/ddg.13191. Epub 2017 
      Feb 27.